Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naratriptan: a review.

N T Mathew1

  • 1Houston Headache Clinic, 1213 Hermann Drive, STE 350, Houston, Texas 77004, USA.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Naratriptan, a 5-HT1B/5-HT1D receptor agonist, offers distinct advantages over sumatriptan for acute migraine treatment due to its favorable pharmacokinetics and prolonged efficacy. Its high bioavailability and low recurrence rate make it a compelling therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.

Neurology·2012
Same author

Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study.

Neurology·2007
Same author

Review of clinical trials using early acute intervention with oral triptans for migraine management.

International journal of clinical practice·2006
Same author

Pathophysiology, epidemiology, and impact of migraine.

Clinical cornerstone·2003
Same author

Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study.

Neurology·2003
Same author

'Side locked' migraine and trigeminal autonomic cephalgias: evidence for clinical overlap.

Cephalalgia : an international journal of headache·2003
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Therapeutics

Background:

  • Naratriptan and sumatriptan are both 5-HT1B/5-HT1D receptor agonists used for acute migraine.
  • Their biological and pharmacokinetic profiles differ significantly, impacting clinical utility.

Purpose of the Study:

  • To compare the distinct clinical therapeutic profile of naratriptan relative to sumatriptan.
  • To highlight the pharmacokinetic and pharmacodynamic advantages of naratriptan in migraine management.

Main Methods:

  • Pharmacokinetic analysis comparing plasma half-life, oral bioavailability, and lipophilicity.
  • Evaluation of clinical efficacy, tolerability, and headache recurrence rates.

Main Results:

  • Naratriptan exhibits a 6-hour plasma half-life, 63-74% oral bioavailability, and higher lipophilicity than sumatriptan.

Related Experiment Videos

  • Naratriptan demonstrated similar tolerability to placebo, prolonged efficacy (>24 hours), and a very low headache recurrence rate.

    • Conclusions:

    • Naratriptan's distinct pharmacokinetic profile translates to a unique clinical therapeutic advantage.
    • The favorable tolerability, prolonged efficacy, and low recurrence rate position naratriptan as an attractive option for acute migraine treatment.